158985-25-2

Basic information

• Product Name: 1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE
• Synonyms: 4-(4-HYDROXY-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-(4-HYDROXY-PHENYL)-PIPERAZINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE;N-Boc-4-(4-hydroxyphenyl)piperazine;tert-Butyl 4-(4-hydroxyphenyl)piperazine-1-carboxylate;1-Boc-4-(4-Hydroxy-P
• CAS NO: 158985-25-2
• Molecular Formula: C₁₅H₂₂N₂O₃
• Molecular Weight: 278.35
• Product Categories: pharmacetical
• Mol File: 158985-25-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE(158985-25-2)
• EPA Substance Registry System: 1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE(158985-25-2)

Safety Data

• Hazardous Substances Data: 158985-25-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be modified and designed into new compounds with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE is utilized as a component in the development of agrochemical products, contributing to the creation of effective and novel solutions for agricultural challenges.
Used in Research and Development:
1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE serves as a valuable compound in research and development settings, where its unique structure allows for the exploration of new chemical pathways and the invention of innovative compounds.
Used in Bioconjugate Development:
1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE is used as a component in the development of bioconjugates, taking advantage of its 4-hydroxyphenyl substituent to create targeted and specific biological interactions.
Used in Targeted Drug Delivery Systems:
In the field of drug delivery, 1-BOC-4-(4-HYDROXY-PHENYL)-PIPERAZINE is employed in the design of targeted drug delivery systems, leveraging its structural features to improve the efficiency and precision of therapeutic agents.

Upstream product

• 106-41-2 4-bromo-phenol 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 56621-48-8 1-(4-hydroxyphenyl)piperazine 
• 34619-03-9 tert-butyldicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 36603-49-3 4-(tetrahydropyran-2'-yloxy)-1-bromobenzene 
• 123-30-8 4-amino-phenol 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 352437-09-3 tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate 
• 470478-90-1 tert-butyl 4-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate 

Downstream Products

• 1016167-50-2 4-[4-(2-tosylethoxy)phenyl]piperazine-1-carboxylic acid t-butyl ester 
• 1198177-59-1 4-[4-(tert-butyldiphenylsilanyloxy)phenyl]piperazine-1-carboxylic acid tert-butyl ester 
• 1379522-35-6 tert-butyl 4-(4-{[4-(methylsulfonyl)benzyl]oxy}phenyl)piperazine-1-carboxylate 
• 1082545-41-2 C₁₃H₁₈N₂O 
• 1450905-44-8 tert-butyl 4-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)piperazine-1-carboxylate 
• 163521-12-8 vilazodone 

Relevant articles and documents

Affinity-Based Selectivity Profiling of an In-Class Selective Competitive Inhibitor of Acyl Protein Thioesterase 2

Activity-based protein profiling (ABPP) has revolutionized the discovery and optimization of active-site ligands across distinct enzyme families, providing a robust platform for in-class selectivity profiling. Nonetheless, this approach is less straightfo

TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF

Disclosed herein are analogues of itraconazole that are potent hedgehog signaling pathway inhibitors. The compounds are expected to be useful in the treatment of cell proliferation disorders such as cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.

ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF

Disclosed herein are compounds, compositions, and methods for modulating the A2A2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties

We conducted a structure-activity relationship study to explore simplified analogues of the itraconazole (ITZ) scaffold for their ability to inhibit the hedgehog (Hh) signaling pathway. These analogues were based on exploring the effects of chemical modifications to the linker and triazolone/side chain region of ITZ. Analogue 11 was identified as the most potent compound in our first generation, with an IC50 value of 81 nM in a murine Hh-dependent basal cell carcinoma. Metabolic identification studies led us to identify truncated piperazine (26) as the major metabolite in human liver microsomes (HLMs) and an improved Hh pathway inhibitor (IC50 = 22 nM). This work verifies that continued truncation of the ITZ scaffold is a practical method to maintain potent anti-Hh activity while also reducing the molecular weight for the ITZ scaffold and achieving improved pharmacokinetic properties.

Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region

Pyroglutamate-modified amyloid β peptides (pGlu-Aβ) are highly neurotoxic and promote the formation of amyloid plaques. The pGlu-Aβ peptides are generated by glutaminyl cyclase (QC), and recent clinical studies indicate that QC represents an alternative t

N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION

This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

ANTIMYCOTIC TRIAZOLE COMPOUND

The invention relates to Compound (I), which is 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)-N-(4-fluorophenyl)benzamide, or a pharmaceutically acceptable salt thereof, usefu

A process for the preparation of intermediates [...] and the intermediate

The invention discloses a preparation method of a vilazodone intermediate and an intermediate. The preparation method of the vilazodone intermediate (5-piperazinylbenzofuran-2-formylimine salts) comprises a step of soaking a compound represented by the formula 7 in a water solution of an inorganic strong acid to carry out hydrolysis deprotection salt-forming reactions, which are represented in the description; wherein the X represents an inorganic strong acid, and the inorganic strong acid can be hydrochloric acid, sulfuric acid, or hydrobromic acid. The invention also discloses a preparation method of a compound represented by the formula 7 and a compound represented by the formula 6. The provided preparation method has the advantages of high yield, easy purification, high purity, and low cost, and is suitable for industrial massive production.

Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents

Novel polar functionalities containing 6-nitro-2,3-dihydroimidazooxazole (NHIO) analogues were synthesized to produce a compound with enhanced solubility. Polar functionalities including sulfonyl, uridyl, and thiouridyl-bearing NHIO analogues were synthes